Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 7/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872772 | 1.00 | BRD4 (0.49) | BRD4ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL18591884 | 0.91 | ALDH1A1 (0.44) | BRD4ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL30411459 | 0.89 | ALDH1A1 (0.53) | BRD4ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL31498654 | 0.88 | MAPT (0.40) | BRD4ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL30869908 | 0.86 | BRD4 (0.38) | BRD4ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL23728786 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL19136021 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL15281425 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL24500208 | 0.85 | ALDH1A1 (0.48) | BRD4ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL29424177 | 0.85 | MAPT (0.39) | BRD4ALDH1A1MAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20220177490-A1 | COMPOUNDS HAVING BOTH EFFECTS OF BET BROMODOMAIN PROTEIN INHIBITION AND PD-L1 GENE REGULATION | MEDSHINE DISCOVERY INC. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | TENSHA THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2569434-B1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA AND RELATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180237454-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| EP-2571875-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571503-A2 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2569429-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | Dana-Farber Cancer Institute, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143669-A2 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA-FARBER CANCER INSTITUTE, INC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | BRD4 891/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20180237454-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | BRD4 3192/4885ALDH1A1 1692/4885MAPT 4052/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | BRD4 891/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20220177490-A1 | COMPOUNDS HAVING BOTH EFFECTS OF BET BROMODOMAIN PROTEIN INHIBITION AND PD-L1 GENE REGULATION | BET1, BRD4, BRD3 | BRD4 2/4885ALDH1A1 2723/4885MAPT 2624/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | BRD4 3/4885ALDH1A1 4275/4885MAPT 2993/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | BRD4 4/4885ALDH1A1 3365/4885MAPT 2849/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | BRD4 4/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | GPR119, IAPP, SLC5A2 | BRD4 1068/4885ALDH1A1 1486/4885MAPT 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.